Compare ACADIA Pharmaceuticals Inc. (ACAD) vs D R Horton Inc (DHI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs D R Horton Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while D R Horton Inc trades at $148.02 (market cap $44.16B). The key difference: D R Horton Inc is far larger — about 9.8× ACADIA Pharmaceuticals Inc.'s market cap, and D R Horton Inc pays a 1.16% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | DHI | |
|---|---|---|
Market Cap | $4.49B | $44.16B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $184.04 |
52-Week Low | $20.06 | $129.82 |
Enterprise Value | $3.69B | $48.87B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
D.R. Horton (DHI) trades at $155.72, down 1.8% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The stock faces headwinds from declining revenue and profit margins, with 2025 revenue dropping to $34.25B and net income falling to $3.59B. Recent earnings show mixed results with Q3 2025 missing expectations but Q4 2025 and Q1 2026 beating estimates. The company maintains strong operational cash flow of $3.42B despite a net cash outflow of $1.51B in 2025.
DHI presents a cautious opportunity with attractive valuation metrics (P/E 14.73, P/S 1.39) below sector averages, but faces significant housing market challenges. Analyst consensus leans neutral with 44% buy ratings and a $163.13 price target offering 4.8% upside. Key risks include housing market volatility, interest rate sensitivity, and competitive pressures in the homebuilding sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →
